Clinical Trial | By Samman Tahhan A, Sandesara P, Quyyumi AA et al.
BACKGROUND - The associations between high-sensitivity troponin I (hsTnI) levels and coronary artery disease (CAD) severity and progression remain unclear. We investigated whether there is an association between hsTnI and angiographic severity and progression of CAD and whether the predictive value of hsTnI level for incident cardiovascular outcomes is independent of CAD severity. METHODS AND RESULTS...
Clinical Trial | By Rigatelli G, Zuin M, Karamfilof K et al.
BACKGROUND - The optimal final optimization technique to be used in patients after Cross Over Left main stenting remains debatable. AIM - We evaluate the impact of the post-optimization technique (POT), kissing balloon (KB) and the POT-side-POT techniques on both cardiovascular mortality and event-free survival in patients receiving left main (LM) cross-over stenting for an isolated/distal bifurcation LM di...
Clinical Trial | By Cardinale D, Latini R, ICOS-ONE Study Investigators et al.
BACKGROUND - Troponin changes over time have been suggested to allow for an early diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin elevation may benefit of therapy with enalapril. It is unknown whether a preventive treatment with enalapril may further increase the benefit. METHODS - The International CardioOncology Society-one trial (ICOS-ONE) was a controlled, open-lab...
Clinical Trial | By van Everdingen WM, Zweerink A, Cramer MJ et al.
BACKGROUND - Previous studies indicated the importance of the intrinsic left ventricular (LV) electric delay (QLV) for optimal benefit to cardiac resynchronization therapy. We investigated the use of QLV for achieving optimal acute hemodynamic response to cardiac resynchronization therapy with a quadripolar LV lead. METHODS AND RESULTS - Forty-eight heart failure patients with a left bundle branch...
Original Research | By FC Liu, DF Gua, XF Lu et al.
Evidence on the lifetime risk for atherosclerotic cardiovascular disease (ASCVD) is insufficient; yet, estimating an individual’s lifetime risk allows for a comprehensive assessment of ASCVD burden. We developed and validated lifetime risk prediction equations for ASCVD using four large and ongoing prospective cohorts of Chinese, the China-PAR project (Prediction for ASCVD Risk in China). Sex-specific equations were develope...
Original Research | By XL Yang, JX Li, DF Gu et al.
BACKGROUND - The accurate assessment of individual risk can be of great value to guiding and facilitating the prevention of atherosclerotic cardiovascular disease (ASCVD). However, prediction models in common use were formulated primarily in white populations. The China-PAR project (Prediction for ASCVD Risk in China) is aimed at developing and validating 10-year risk prediction equations for ASCVD from 4 contemporar...
Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension
Original Research | By Hjalmarsson C, Rådegran G, Kylhammar D et al.
Recent reports from worldwide pulmonary hypertension registries show a new demographic picture for patients with idiopathic pulmonary arterial hypertension (IPAH), with an increasing prevalence among the elderly. We aimed to investigate the effects of age and comorbidity on risk stratification and outcome of patients with incident IPAH. The study population (n=264) was categorised into four age groups: 18-45, 46-64, 65-74 and ≥75 years....
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
Original Research | By Coghlan JG, Denton CP, DETECT study group.
OBJECTIVE - Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in systemic sclerosis (SSc), facilitates earlier treatment. The objective of this study was to develop the first evidence-based detection algorithm for PAH in SSc. METHODS - In this cross-sectional, international study conducted in 62 experienced centres from North America, Europe and Asia, adults with SSc at incr...
Clinical and genetic characteristics of pulmonary arterial hypertension in Lebanon
Clinical Trial | By Abou Hassan OK, Haidar W, BouAkl I et al.
BACKGROUND - Pulmonary arterial hypertension (PAH) is a rare disease with an incidence rate of 2-6 cases per million per year. Our knowledge of the disease in the Middle East and North Africa (MENA) region is limited by the small number of clinical studies and the complete absence of genetic studies. METHODS - Our aim was to shed light on the clinical and genetic characteristics of PAH in Lebanon an...